永安药业（002365）发布异动公告，公司股票于2025年5月21日、22日连续两个交易日内日收盘价格涨 幅偏离值累计超出20%，属于股票交易异常波动情况。公司提醒投资者注意投资风险，理性决策。公司 静态市盈率和滚动市盈率高于所属行业水平，且2025年一季度处于亏损状态。此外，公司实际控制人、 董事长被留置的事项仍在进展中。公司目前没有应披露而未披露的重大事项，且不存在违反信息公平披 露的情形。 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-35 潜江永安药业股份有限公司 关于股票交易异常波动暨风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易价格于 2025 年 5 月 21 日、2025 年 5 月 22 日连续 两个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳证券交易所的有关 规定，属于股票交易异常波动的情况。公司股价短期涨幅较大，敬请广大投资者 理性投资，注意投资风险。 2、截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市 盈率为 80.30，滚动市盈率为 172.69；公司所属中上协行业分类"医药制造业" 的静态市盈率为 28.46，滚动市盈率为 28.01。公司静态市盈率、滚动市盈率高 于公司所属中上协行业分类"医药制造业"水平。2025 年一季度，公司处于亏 损状态。公司特别提醒投资 ...

石墨电极概念资金流出榜 截至5月22日收盘，石墨电极概念下跌2.91%，位居概念板块跌幅榜前列，板块内，翔丰华、中科电 气、道氏技术等跌幅居前，股价上涨的有2只，涨幅居前的有永安药业、国民技术等，分别上涨 9.98%、0.21%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 手机游戏 | 0.33 | 环氧丙烷 | -3.41 | | 太赫兹 | 0.32 | 石墨电极 | -2.91 | | Sora概念(文生视频) | 0.31 | 代糖概念 | -2.86 | | 智能音箱 | 0.18 | 钠离子电池 | -2.83 | | 军工信息化 | 0.14 | 转基因 | -2.81 | | 无线充电 | 0.11 | 光刻胶 | -2.76 | | 语音技术 | 0.11 | 草甘膦 | -2.73 | | 多模态AI | -0.04 | 固态电池 | -2.56 | | 网约车 | -0.15 | 宠物经济 | -2.49 | | 网络游戏 | -0.16 | 供销社 | -2.43 | 资金面上看 ...

永安药业午后涨停，走出两连板。 ...

Group 1 - The graphite electrode concept sector increased by 2.57%, ranking first among concept sectors, with 17 stocks rising, including Ningxin New Materials which hit a 30% limit up, and Yong'an Pharmaceutical also hitting the limit up, while Dongfang Carbon, Xiangfenghua, and Better Ray saw increases of 11.54%, 5.78%, and 3.30% respectively [1][2] - The sector attracted a net inflow of 263 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan, led by Yong'an Pharmaceutical with a net inflow of 260 million yuan [2][3] - The top three stocks by net inflow ratio were Yong'an Pharmaceutical at 20.71%, China Baoan at 17.14%, and Xiangfenghua at 10.64% [3][4] Group 2 - The top performing stocks in the graphite electrode concept included Yong'an Pharmaceutical, with a daily increase of 10.00% and a turnover rate of 30.78%, followed by Daoshi Technology and Zhongke Electric with increases of 2.77% and 3.28% respectively [3][4] - The stocks with the largest declines included Fuan Co., which fell by 2.92%, and Guomin Technology and Shanshan Co., which decreased by 1.95% and 1.56% respectively [1][4] - The overall market performance showed a mixed trend, with several sectors experiencing declines, while the graphite electrode sector stood out with significant gains [2][3]

Core Viewpoint - Yong'an Pharmaceutical has seen a significant stock price increase, reaching a new high of 15.41 yuan per share, attributed to rising export prices of taurine products and strong market interest in the taurine industry [1][4]. Company Performance - As of May 19, Yong'an Pharmaceutical's stock price increased by 9.99%, with a net inflow of 182 million yuan in main funds on that day [1][2]. - Since April 1, the company's stock has risen by 86.11%, with three limit-up days in four trading sessions following a limit-up on May 14 [4]. - The company reported a net profit of 61.76 million yuan for 2024, marking a turnaround from losses [5]. Industry Context - Yong'an Pharmaceutical is a leading player in the taurine industry, holding over 50% of the global market share with an annual production capacity of 58,000 tons [4]. - The export prices for pharmaceutical-grade taurine reached 8.9 USD per kilogram and food-grade taurine at 6.89 USD per kilogram in April, indicating a significant price increase [4]. - The market has shown increased interest in the taurine supply chain, with related sectors such as health products and pet economy performing well, supporting Yong'an Pharmaceutical's stock price rise [5]. Management and Governance - The company is actively engaged in the research, production, and sales of functional foods and health products through its subsidiary, Yong'an Kangjian Pharmaceutical [5]. - There is ongoing market attention regarding the investigation of the company's chairman, which may impact operational decisions and market confidence [6].

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical (002365) has experienced a significant stock price increase of 9.99% as of May 19, 2025, closing at 15.41 yuan, with a trading volume of 507,300 hands and a transaction amount of 767 million yuan [1] - The company reported a total operating revenue of 171 million yuan for Q1 2025, representing a year-on-year decrease of 12.96%, and a net profit attributable to shareholders of 4.37 million yuan, down 115.23% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 5.289 and a quick ratio of 4.876, while the debt-to-asset ratio stands at 10.45% [1] Group 2 - Yong'an Pharmaceutical has made investments in 8 external companies and participated in 20 bidding projects, indicating active engagement in business expansion [2] - The company holds 3 trademark registrations and 39 patents, showcasing its commitment to intellectual property development [2] - Yong'an Pharmaceutical has obtained 278 administrative licenses, reflecting its compliance and operational capabilities within the industry [2]

截至5月15日收盘，宠物经济概念上涨1.98%，位居概念板块涨幅第3，板块内，54股上涨，美农生物、 洁雅股份等20%涨停，若羽臣、永安药业、*ST绿康等涨停，仙乐健康、回盛生物、一致魔芋等涨幅居 前，分别上涨13.41%、10.50%、9.10%。跌幅居前的有致欧科技、青木科技、萤石网络等，分别下跌 4.64%、4.42%、2.73%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | NMN概念 | 2.07 | 华为盘古 | -3.76 | | 合成生物 | 2.05 | DRG/DIP | -3.30 | | 宠物经济 | 1.98 | 华为昇腾 | -3.09 | | 中韩自贸区 | 1.96 | 智谱AI | -3.09 | | 乳业 | 1.67 | 数字货币 | -3.05 | | 维生素 | 1.55 | 财税数字化 | -3.05 | | 玉米 | 1.54 | 华为鲲鹏 | -3.05 | | 动物疫苗 | 1.28 | MLOps概念 | -3.04 | | 转基因 | 1.23 | 华 ...

二、公司关注、核实情况说明 证券代码：002365 证券简称：永安药业 公告编号：2025-34 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 5 月 14 日、2025 年 5 月 15 日连续两 个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳证券交易所的有关规 定，属于股票交易异常波动的情况。 （五）经核查，公司未发现其他应披露而未披露事项。 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 （二）自公司发布《关于公司实际控制人、董事长被留置的公告》（公告编 号：2025-31）公告以来，媒体对公司关注度较高。截至本公告披露日，公司暂 未知悉上述事项的进展及结论，公司将持续关注该事项后续进展情况，并根据相 关规定及时履行信息披露义务。除公司已披露的信息外，公司未发现近期公共媒 体报道了可能或者已经对 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-34 潜江永安药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 5 月 14 日、2025 年 5 月 15 日连续两 个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳证券交易所的有关规 定，属于股票交易异常波动的情况。 （五）经核查，公司未发现其他应披露而未披露事项。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协 议等；董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》等有关规 定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 二、公司关注、核实情况说明 针对公司股票交易异常波动 ...